UCL Cancer Institute


UCL Cancer Institute Seminar Series

12 January 2017, 12:00 pm–1:00 pm

Awen Gallimore…

Professor Awen Gallimore, University of Cardiff, presents: Manipulating regulatory T Cells for tumour rejection.

Event Information


UCL Cancer Institute, Paul O'Gorman Building

The journal Science voted 'Cancer Immunotherapy' the most important scientific breakthrough in 2013 due in part to the success of adoptive T cell therapy. However, the success of this treatment and others may be limited by the failure of activated lymphocytes to effectively infiltrate tumors. Using an established mouse model where carcinogen-induced tumours arise in vivo, we have reported that depletion of Foxp3+ regulatory T cells (Tregs), can promote development of specialised blood vessels (high endothelial venules or HEV) in tumours. HEV are normally found only in secondary lymphoid tissue where they facilitate transit of naïve and central memory T cells into the lymph node parenchyma. However, in a recent study HEV have been detected in breast tumours where a significant association between HEV presence and density of tumour-infiltrating lymphocytes (TIL) was observed. Significantly a correlation between the presence of HEV and a favourable prognosis in breast cancer and melanoma patients was reported. In our mouse model of tumorigenesis we also found that the presence of intra-tumoural HEV correlated with a significant increase in the number of TIL and control of tumour growth. Thus, the main objectives of our current work are to determine how HEVs are induced in tumours and the role Tregs play in this process and to test novel immunotherapeutic approaches to drive intra-tumoural HEV neogenesis using established pre-clinical mouse models of cancer. The overall aim is to devise new treatments, combining immunotherapy with regimes designed to alter the tumour vasculature.

Hosted by: Professor Bart Vanhaesebroeck and Dr Sergio Quezada

The seminar will be followed by a sandwich buffet lunch

For further information: Gallimore Godkin Cancer Immunology Lab


Courtyard Café
UCL Cancer Institute
Paul O'Gorman Building
London, WC1E 6DD

Contact: Veronica Dominguez v.dominguez@ucl.ac.uk

This seminar has been part-sponsored by Merck, the Biomedical Research Centre and Cancer Research UK.